Case Report: Pregnancy in a patient with recurrent glioblastoma [version 1; peer review: 2 approved]

Birgit Flechl¹, Marco Ronald Hassler¹, Gerhard Kopetzky², Peter Balcke², Christine Kurz³, Christine Marosi¹,⁴

¹Department of Internal Medicine I, Clinical Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria
²Department of Internal Medicine I, General Hospital of St. Pölten, 3100 St. Pölten, Austria
³Department of Obstetrics and Gynaecology, Clinical Division of Endocrinology, Medical University of Vienna, 1090 Vienna, Austria
⁴Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, 1090 Vienna, Austria

Abstract
We report the case of a woman with relapsed glioblastoma multiforme (GBM) who recently gave birth. She announced her pregnancy shortly after the sixth cycle of a dense regimen of temozolomide, prescribed for treating the first recurrence of glioblastoma. Three years ago, in April 2008, she had undergone gross total resection of a glioblastoma multiforme in the postcentral region of the right hemisphere and had subsequently received treatment according to the actual standard therapy consisting of radiotherapy up to 60 Gy with concomitant and adjuvant temozolomide. The complete amount of temozolomide given before this pregnancy was 20.9 mg/m². Nevertheless, she delivered a 1890 g child by caesarean section in the 32/6 week of pregnancy. The child showed no anomalies and is developing normally under close surveillance by paediatricians.

Keywords
glioblastoma, pregnancy under chemotherapy

Corresponding author: Christine Marosi (christine.marosi@meduniwien.ac.at)
Competing interests: The author(s) declare that they have no competing interests.
Grant information: The Medical University of Vienna supported this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2013 Flechl B et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
First published: 15 Nov 2013, 2:246 https://doi.org/10.12688/f1000research.2-246.v1
**Introduction**

Cases of pregnancy and giving birth are rare in patients with malignant gliomas. Besides the grim prognosis of malignant gliomas, the actual standard therapy of glioblastoma adversely affects fertility. In fact, radiotherapy aimed at the hypothalamus and the pituitary gland exceeding 45 Gy could impair the synthesis of gonadotropins, while chemotherapy with alkylating agents such as temozolomide is associated with impaired ovarian function leading to premature menopause. However, there are some reports of pregnancies in women with malignant gliomas, describing women whose brain tumors were diagnosed during pregnancy, as well as women who already had undergone treatment for malignant gliomas and who became pregnant afterwards. Our recent patient is an example of a patient whose fertility was not suppressed by glioblastoma multiforme (GBM) and its treatment.

**Case**

The patient is a 37 year old woman, born in Austria. She had two children (13 and 15 years) before her GBM diagnosis. She was diagnosed with GBM in the right frontal lobe in April 2008, and treated according to a current treatment standard consisting of a gross total resection of the tumor, fractionated conformal radiotherapy up to 60 Gy (2 Gy/fraction) and concomitant and adjuvant chemotherapy with temozolomide. Diagnosis and treatment were performed at the Medical University of Vienna (MUV). Following the concomitant therapy, she experienced amenorrhoea for 6 months, followed by irregular menstrual cycles with oligomenorrhea. Two years later, a local recurrence of GBM was diagnosed. She underwent a second resection and followed 6 cycles of dose dense temozolomide, 100 mg/m² orally for five days per week, with a drug holiday over every weekend. She became pregnant less than three weeks after the last intake of the sixth cycle of temozolomide, after a total dose of temozolomide of 20.9 g/m² (Table 1).

Both parents wanted to carry the child to term. They were offered intensified pregnancy monitoring and genetic counselling, but no genetic tests were performed. During pregnancy the child developed normally as followed by close meshed ultrasound controls and the mother was doing well until week 27, when she developed signs of increased intracranial pressure as well as weakness of the left leg. She was admitted to the local general hospital for observance and anti edematous treatment. As the mother’s condition worsened, she received corticosteroids to induce lung maturation of the fetus, and the child was delivered after 32 weeks and 6 days of pregnancy by caesarean section using the Misgav Ladach method.

The child showed Apgar scores of 8/9/9, one, five and ten minutes after birth, respectively, weighed 1876 g, cried spontaneously and was neurologically inconspicuous. The infant did not need further respiratory assistance after the third day of life, and was discharged from the neonatal intensive care unit after an uncomplicated stay without any signs of neurological or any other organ deficit, weighing 2.5 kg. The child has shown normal growth and development ever since.

The mother underwent her third neurosurgical procedure two weeks after delivery, followed by chemotherapy with fotemustine 100 mg/m² every three weeks for six cycles combined with bevacizumab 10 mg/kg every two weeks 6 weeks later. Eight months after the caesarean section, distal progression in the brain was diagnosed on MRI and she was referred for radiotherapy of the distant recurrence.

**Discussion**

Temozolomide has been classified to pregnancy category D by the US Food and Drug Administration, which means that animal studies have revealed evidence of embryo lethality induced by the drug. Moreover, malformations have been observed in animals, therefore women are advised to avoid becoming pregnant during temozolomide intake. However, we report here the pregnancy of a woman with GBM, treated with radio/chemotherapy using a protocol described by Stupp et al. and further dose dense temozolomide in relapse 5 days of seven, as described by Strik et al.

There are some previous reports on pregnancies in women with malignant glioma. Nadine Johnson retrospectively reported the obstetric outcomes of women with intracranial neoplasms, from Ontario, Canada, covering the experience of 6000 deliveries. In this database, Johnson et al. identified 25 pregnancies in women who had been diagnosed with intracranial neoplasms, including 12 patients with gliomas. This review discusses neurological deterioration due to the hormonal changes causing fluid retention during pregnancy and the complications and the management of increased cranial pressure at the time of delivery. There are some small series and case reports on the same issues.

Deborah Blumenthal (2008) reported a series of 6 women with malignant glioma with unplanned pregnancies during glioma treatment. Several women even had drug exposure during the first trimester of pregnancy, three with PCV (procarbazine, cyclophosphamide, vincristine), and three with temozolomide. All gave birth to healthy, full term infants with no evidence of congenital malformations. Sadly, five of the six mothers died within the following 2.5 years due to recurrence of disease.

An adverse effect on disease outcome during pregnancy has been observed in six of eight pregnancies in women with low grade gliomas followed by the French low grade glioma (LGG) group, possibly due to the decreased immune surveillance during pregnancy or to the presence of potential hormonal receptors on glioma cells.

In a later series on 12 pregnancies of women with LGG followed by the same research group published 2010, the growth rate of the gliomas increased during pregnancy as measured by successive MRI scans.

However, the prolonged survival of our patient 18+ months after the diagnosis of a relapsed glioblastoma appears noteworthy. This case also should bring to mind the necessity of repeated counseling about contraception – even in patients where the probability of persistent fertility is minimal, as in the patient described in this report. In fact, regardless of all the apprehensions of medical professionals about this pregnancy, the patient and her husband were simply happy about it. They wanted to keep this child, even if it would have meant severe adverse complications for the mother. They perceived this pregnancy as a gift of life and enjoyed every moment, even when it was steadily overshadowed by the glioblastoma. They remembered perfectly well that they had been told that pregnancy should be avoided during and after the glioma treatment,
and that they even had signed this as a part of the regular consent for treatment, but on the other hand they told us that this pregnancy had been the only happy event for them in all those years.

They also tried to organize further care for the child, as the possibility of the baby losing its mother during childhood is very high. As the patient and her husband are aware of the grim prognosis of recurrent GBM, they planned to raise the child with multiple psychological parents, including its grown up siblings and the two sisters of the mother.

**Conclusion**

This report shows that pregnancy and the birth of a healthy infant can occur even in women that have been heavily pretreated with alkylating agents and that conception can occur as early as three weeks after the last intake of chemotherapy.

**Consent**

Written informed consent was obtained from the patient for the publication of this case report.

**Table 1. Total temozolomide dose before the pregnancy.**

<table>
<thead>
<tr>
<th>Temozolomide scheme</th>
<th>Temozolomide dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant phase</td>
<td>42 days at 75 mg/m²</td>
</tr>
<tr>
<td></td>
<td>3150 mg/m²</td>
</tr>
<tr>
<td>Adjuvant treatment</td>
<td>5× 150 mg/m²+ 5× 5×200 mg/m²</td>
</tr>
<tr>
<td></td>
<td>5750 mg/m²</td>
</tr>
<tr>
<td>Dose 1st line treatment</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>8900 mg/m²</td>
</tr>
<tr>
<td>Dose temozolomide relapse</td>
<td>6× 100 mg/m² x 5 days x 4 weeks/month</td>
</tr>
<tr>
<td></td>
<td>12000 mg/m²</td>
</tr>
<tr>
<td>Total dose</td>
<td>20.900 mg/m²</td>
</tr>
</tbody>
</table>

**Author contributions**

BF was a major contributor in writing and interpreting the manuscript. RMH has made substantial contributions to the conception and design of the manuscript. GK and PB delivered essential patient data. CK was involved in revising the report critically for important intellectual content. CM made substantial contributions to the conception and design of the report, coordinated the tasks and timelines and was involved in writing and interpreting the manuscript. All authors read and approved the final version of the manuscript.

**Competing interests**

The author(s) declare that they have no competing interests.

**Grant information**

The Medical University of Vienna supported this work.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**References**


Open Peer Review

Current Peer Review Status: ✔️ ✔️

Version 1

Reviewer Report 21 March 2014

https://doi.org/10.5256/f1000research.2872.r4214

© 2014 Thiet M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mari-Paule Thiet
Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA, USA

This article describes a single case of pregnancy following a diagnosis and treatment of recurrent glioblastoma. It illustrates that spontaneous pregnancy can be achieved after high doses of chemotherapy. There is a review of the current literature regarding outcomes of pregnancy in patients with brain tumors.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 14 January 2014

https://doi.org/10.5256/f1000research.2872.r3122

© 2014 Blumenthal D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Deborah Blumenthal
Oncology Division, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

The report, "Pregnancy in a patient with recurrent glioblastoma" illustrates a notable case of a 37 year-old woman with recurrent glioblastoma (GB) who became pregnant within 3 weeks of a (6-cycle) dose-dense temozolomide regimen. The case is notable for preservation of fertility, essentially during alkylating treatment; positive outcome of the child at planned 32 week delivery by C-section and normal growth and development at 18 months; and for survival of the mother
with recurrent GB 18+ months from recurrence.

The authors mention prior related works in the literature regarding the effects of pregnancy on patients with malignant glioma; a series of patients who conceived (with positive fetal outcome) during active alkylator treatment and documentation of accelerated growth rates of gliomas during pregnancy.

This report is encouraging for those patients concerned about fertility issues, but should not be interpreted as a guarantee for either male or female patients that fertility will be preserved after alkylating chemotherapy. Additionally, a disclaimer should be made for the potential (confirmed by animal studies on embryo-lethality with exposure to these drugs) danger to the exposed fetus, despite the reported good outcomes of these children.

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**